
Two years after Alex Denner activist attack, Ironwood plots mass layoffs as last clinical program goes up in smoke
A year and a half ago, when Ironwood finished splitting itself in two, they were left with just a pair of experimental medicines in the clinic: a reformulation of Linzess, their approved drug for irritable bowel syndrome, and a new drug for persistent acid reflux called IW-3718.
In May, the Linzess formulation failed a Phase II study. And now, in part two of a year-long double-whammy for the Boston pharma, IW-3718 proved ineffective in its own large study. Both programs will be discontinued, marking a major setback for Ironwood and leaving the company facing an empty pipeline, huge layoffs and, two years splitting amid pressure from Alex Denner, another restructuring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.